BIT
ESPR

BlackRock Institutional Trust’s Esperion Therapeutics ESPR Stock Holding History

BlackRock Institutional Trust’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$4.99M Hold
398,499
– – ﹤0.01% 2730
2016
Q3 		$5.52M Buy
398,499
+45,793
+13% +$519K ﹤0.01% 2650
2016
Q2 		$3.48M Buy
352,706
+21,756
+7% +$361K ﹤0.01% 2834
2016
Q1 		$5.6M Buy
330,950
+4,471
+1% +$71.9K ﹤0.01% 2594
2015
Q4 		$7.27M Buy
326,479
+6,307
+2% +$159K ﹤0.01% 2518
2015
Q3 		$7.55M Buy
320,172
+15,752
+5% +$989K ﹤0.01% 2476
2015
Q2 		$24.9M Buy
304,420
+99,232
+48% +$9.71M ﹤0.01% 1771
2015
Q1 		$19M Buy
205,188
+118,358
+136% +$7.64M ﹤0.01% 1976
2014
Q4 		$3.51M Buy
86,830
+16,481
+23% +$504K ﹤0.01% 2874
2014
Q3 		$1.72M Sell
70,349
-3,176
-4% -$50.5K ﹤0.01% 3142
2014
Q2 		$1.17M Sell
73,525
-1,040
-1% -$15K ﹤0.01% 3397
2014
Q1 		$1.13M Sell
74,565
-18,628
-20% -$289K ﹤0.01% 3378
2013
Q4 		$1.28M Buy
93,193
+13,420
+17% +$195K ﹤0.01% 3321
2013
Q3 		$1.5M Buy
+79,773
New +$1.34M ﹤0.01% 3243

Other funds holding ESPR

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock Institutional Trust's ESPR Position: Q4 2016 in Review

BlackRock Institutional Trust held its Esperion Therapeutics (ESPR) position steady in Q4 2016 at 398,499 shares worth $4.99M. The position accounts for ﹤0.01% of the portfolio, ranked #2730.

BlackRock Institutional Trust first reported a position in ESPR in Q3 2013 and has held it in 14 quarters since. The position peaked at $24.9M in Q2 2015. 99 funds tracked by Wall St. Rank hold ESPR as of Q4 2016.

  • BlackRock Institutional Trust held 398,499 shares of Esperion Therapeutics worth $4.99M as of Q4 2016.
  • BlackRock Institutional Trust left its Esperion Therapeutics share count unchanged in Q4 2016.
  • Esperion Therapeutics made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #2730 holding.
  • BlackRock Institutional Trust first reported a position in Esperion Therapeutics in Q3 2013 and has held it in 14 quarters since.
  • BlackRock Institutional Trust's Esperion Therapeutics position peaked at $24.9M in Q2 2015.
  • 99 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.